Director at Microbot Medical (NASDAQ: MBOT) granted 10,000 stock options at $2.37

Rhea-AI Filing Summary

Microbot Medical Inc. director David James Wilson received a grant of stock options covering 10,000 shares of common stock. The options were awarded at an exercise price of $2.37 per share, carry no upfront cost, and were granted on April 1, 2026.

These options give him the right to buy 10,000 shares of Microbot Medical common stock at $2.37 per share until their expiration on April 1, 2036. After this grant, he holds 10,000 stock options directly, with no additional derivative positions shown in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wilson David James

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	10,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 10,000 shares (Direct)

Footnotes (1)

Key Figures

Options granted: 10,000 options Exercise price: $2.37 per share Expiration date: April 1, 2036 +2 more

5 metrics

Options granted 10,000 options Stock Option (Right to Buy) granted April 1, 2026

Exercise price $2.37 per share Exercise price of granted stock options

Expiration date April 1, 2036 Expiration of stock option grant

Underlying shares 10,000 shares Common stock underlying the stock options

Options held after grant 10,000 options Total derivative holdings following the transaction

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, par value $0.01 per share, Form 4

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Stock, par value $0.01 per share financial

"underlying_security_title: "Common Stock, par value $0.01 per share""

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wilson David James

(Last) (First) (Middle)

C/O MICROBOT MEDICAL INC.

175 DERBY ST., BLD. 27

(Street)

HINGHAM MASSACHUSETTS 02043

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Microbot Medical Inc. [ MBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.37	04/01/2026		A		10,000		04/01/2026	04/01/2036	Common Stock, par value $0.01 per share	10,000	$0	10,000	D

Explanation of Responses:

	/s/ David J. Wilson	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Microbot Medical (MBOT) report for David James Wilson?

Microbot Medical reported that director David James Wilson received a grant of stock options for 10,000 shares. These options were awarded as a compensation-related grant, not an open-market purchase, and give him the right to buy common stock at a fixed exercise price.

How many Microbot Medical (MBOT) options were granted to the director?

The director was granted stock options covering 10,000 shares of Microbot Medical common stock. This means he can potentially purchase up to 10,000 shares in the future at the specified exercise price if the options vest and he chooses to exercise them.

What is the exercise price of the new Microbot Medical (MBOT) stock options?

The newly granted stock options have an exercise price of $2.37 per share. This price is the fixed amount the director must pay per share if he exercises the options to acquire Microbot Medical common stock at any time before expiration.

When do the granted Microbot Medical (MBOT) stock options expire?

The stock options granted to the director expire on April 1, 2036. Up until that expiration date, and subject to any vesting conditions under the award, he may choose to exercise the options to buy Microbot Medical common stock at the $2.37 exercise price.

Is the Microbot Medical (MBOT) Form 4 transaction a market purchase or a grant?

The Form 4 transaction is a grant of stock options, not a market purchase. The filing classifies it as a “Grant, award, or other acquisition,” meaning the director received options from the company as compensation rather than buying shares on the open market.

How many Microbot Medical (MBOT) options does the director hold after this grant?

After this grant, the director holds 10,000 stock options directly, according to the filing. These options relate to an equal number of underlying common shares and represent his derivative position as of the transaction date reported in the Form 4.